{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:34Z","timestamp":1793640754640,"version":"4.5.1"},"reference-count":30,"publisher":null,"issue":"11","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim<\/jats:italic>\n                    \u00a0 \u00a0Analysis of the cardioprotective effectivity of chronopharmacotherapy in patients with arterial hypertension (AH) after transient ischemic attack (TIA).\n                    <jats:italic>Material and methods<\/jats:italic>\n                    \u00a0 \u00a0174 patients with AH and TIA were evaluated. All patients were randomized to three groups based on the dosing schedule of chronopharmacotherapy: group 1 (n=59), patients receiving indapamide retard 1.5 mg and valsartan 160 mg, both in the morning; group 2 (n=58), indapamide retard 1.5 mg in the morning and valsartan 160 mg in the evening; group 3 (n=57), indapamide retard 1.5 mg in the morning and valsartan 80 mg in the morning and evening. Echocardiography (EchoCG) (ALOKA SSD 2500, Japan) was performed for all patients at baseline and at 12 months of the treatment. Statistical analysis of results was performed with the Statistica 12.0 (StatSoftInc, USA) software.\n                    <jats:italic>Results<\/jats:italic>\n                    \u00a0 \u00a0Before the treatment, EchoCG parameters did not significantly differ between the patient groups. After 12 months of the treatment, positive changes in the end-systolic dimension (ESD), interventricular septal thickness (IVST), thickness of the left ventricular posterior wall (TLVPW), LV myocardial mass (LVMM), LVMM index (LVMMI), ejection fraction (EF), ratio of transmitral early peak flow velocity and late filling flow velocity (E\/A), and isovolumetric velocity relaxation time (IVRT) were more pronounced in the group of sartan evening dosing (group 2) than in the group of sartan single morning dosing (group 1) (p&lt;0.05). In group 3, the changes in ESD, IVST, TLVPW, LVMM, LVMMI, EF, E\/A ratio, deceleration time (DT) of LV, and IVRT were significantly greater than those in group 1, whereas the dynamics of ESD, IVST, TLVPW, LVMM, LVMMI, E\/A ratio, and DT were better in group 3 than in group 2 (p&lt;0.05). In addition, a significantly greater number of patients with normalized LV geometry was registered in group 3 compared to groups 1 and 2 (p&lt;0.05). The number of patients with normal LV diastolic function after the treatment was also significantly greater in group 3 than in group 1 (p&lt;0.05) and comparable with group 2.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    \u00a0 \u00a0The morning dosing of indapamide retard and the b.i.d. dosing of valsartan provided more pronounced beneficial changes in major EcoCG indexes and improvement of LV geometry and diastolic function than the sartan single dosing only in the morning or evening in combination with the diuretic.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2021.11.n1854","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T09:36:36Z","timestamp":1639042596000},"page":"33-41","source":"Crossref","is-referenced-by-count":0,"title":["Cardioprotective potential of chronopharmacotherapy in patients with arterial hypertension who had a transient ischemic attack"],"prefix":"10.68900","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-2887","authenticated-orcid":true,"given":"S. V.","family":"Opolskaya","sequence":"first","affiliation":[{"name":"Kuban State Medical University of the Ministry of Health of Russia, Krasnodar, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4855-418X","authenticated-orcid":true,"given":"V. V.","family":"Skibitsky","sequence":"additional","affiliation":[{"name":"Kuban State Medical University of the Ministry of Health of Russia, Krasnodar, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4323-0813","authenticated-orcid":true,"given":"A. V.","family":"Fendrikova","sequence":"additional","affiliation":[{"name":"Kuban State Medical University of the Ministry of Health of Russia, Krasnodar, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8476-7641","authenticated-orcid":true,"given":"T. B.","family":"Zabolotskich","sequence":"additional","affiliation":[{"name":"Kuban State Medical University of the Ministry of Health of Russia, Krasnodar, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6833-9033","authenticated-orcid":true,"given":"A. V.","family":"Skibitsky .","sequence":"additional","affiliation":[{"name":"Kuban State Medical University of the Ministry of Health of Russia, Krasnodar, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149\u2013218. DOI: 10.15829\/1560-4071-2020-3-3786","DOI":"10.15829\/1560-4071-2020-3-3786"},{"key":"ref2","unstructured":"Alferova V.V., Belkin A.A., Voznyuk I.A., Gerasimenko M.Yu., Geraskina L.A., Gordeev M.N. et al. Clinical guidelines for the management of patients with ischemic stroke and transient ischemic attacks. \u2013 M.: MEDPress;2017. - 208 p. ISBN 978-5-00030-450-1"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Skvortsova V.I., Stakhovskaya L.V., Ayriyan N.Yu. Epidemiology of stroke in the Russian Federation. Systemic Hypertension. 2005;2(1):10\u20132. DOI: 10.26442\/SG28725","DOI":"10.26442\/SG28725"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Amarenco P, Lavall\u00e9e PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H et al. Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. New England Journal of Medicine. 2018;378(23):2182\u201390. DOI: 10.1056\/NEJMoa1802712","DOI":"10.1056\/NEJMoa1802712"},{"key":"ref5","unstructured":"Panuganti KK, Tadi P, Lui F. Transient Ischemic Attack. In: StatPearls. \u2013 Treasure Island (FL): StatPearls Publishing;2021. [PMID: 29083778]"},{"key":"ref6","unstructured":"Parfenov V.A., Ragimov S.K. Prognosis of transitory ischemic attacks based on 1-year follow-up results. Neurological Journal. 2011;16(2):23\u20136."},{"key":"ref7","unstructured":"Strutynskiy A.V., Golubev Yu.Yu., Strutynskiy V.A., Trishina V.V., Beketova E.Yu., Shvedov Yu.A. et al. Echocardiographic markers of increased risk of ischemic stroke in patients with hypertension. Medical business. 2018;1:72\u201381. DOI: 10.24411\/2071-5315-2018-11986"},{"key":"ref8","unstructured":"Chelysheva I.A., Gerassimova Yu.A., Linkov V.V., Bunina I.S. Risk factors for ischemic stroke and myocardial infarction combination. Bulletin of the Ivanovo Medical Academy. 2016;21(4): 52\u20133."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gallicchio L, Kalesan B. Sleep duration and mortality: a systematic review and meta-analysis. Journal of Sleep Research. 2009;18(2):148\u201358. DOI: 10.1111\/j.1365-2869.2008.00732.x","DOI":"10.1111\/j.1365-2869.2008.00732.x"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Omama S, Yoshida Y, Ogawa A, Onoda T, Okayama A. Differences in circadian variation of cerebral infarction, intracerebral haemorrhage and subarachnoid haemorrhage by situation at onset. Journal of Neurology, Neurosurgery & Psychiatry. 2006;77(12):1345\u20139. DOI: 10.1136\/jnnp.2006.090373","DOI":"10.1136\/jnnp.2006.090373"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Turin TC, Kita Y, Rumana N, Nakamura Y, Takashima N, Ichikawa M et al. Is there any circadian variation consequence on acute case fatality of stroke? Takashima Stroke Registry, Japan (1990-2003). Acta Neurologica Scandinavica. 2012;125(3):206\u201312. DOI: 10.1111\/j.1600-0404.2011.01522.x","DOI":"10.1111\/j.1600-0404.2011.01522.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033\u201341. DOI: 10.1016\/S0140-6736(01)06178-5","DOI":"10.1016\/S0140-6736(01)06178-5"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential Impact of Blood Pressure\u2013Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006;113(9):1213\u201325. DOI: 10.1161\/CIRCULATIONAHA.105.595496","DOI":"10.1161\/CIRCULATIONAHA.105.595496"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Svensson P, de Faire U, Sleight P, Yusuf S, \u00d6stergren J. Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy. Hypertension. 2001;38(6):E28-32. DOI: 10.1161\/hy1101.099502","DOI":"10.1161\/hy1101.099502"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Forette F. The Prevention of Dementia With Antihypertensive TreatmentNew Evidence From the Systolic Hypertension in Europe (SystEur) Study. Archives of Internal Medicine. 2002;162(18):2046\u201352. DOI: 10.1001\/archinte.162.18.2046","DOI":"10.1001\/archinte.162.18.2046"},{"key":"ref16","unstructured":"Agadzhanyan N.A., Petrov V.I., Radysh I.V., Krayushkin S.I. Chronophysiology, chronopharmacology and chronotherapy. -Volgograd: Volgograd State Medical University;2005. - 336 p. ISBN 5-9652-0007-2"},{"key":"ref17","unstructured":"Arushanyuan E.B., Naumov S.S. Chronobiological features of stroke and the protective role of epiphyseal melatonin. Bukovinian Medical Herald. 2009;13(4):10\u20136."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Skibitskiy V.V., Kiselev A.A., Fendrikova A.V. Effectiveness of Chrono-Pharmacotherapy Depending on the Salt Sensitivity of Patients with Arterial Hypertension and Diabetes Mellitus Type 2. Rational Pharmacotherapy in Cardiology. 2019;14(6):846\u201351. DOI: 10.20996\/1819-6446-2018-14-6-846-851","DOI":"10.20996\/1819-6446-2018-14-6-846-851"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Hermida RC, Crespo JJ, Dom\u00ednguez-Sardi\u00f1a M, Otero A, Moy\u00e1 A, R\u00edos MT et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. European Heart Journal. 2020;41(48):4565\u201376. DOI: 10.1093\/eurheartj\/ehz754","DOI":"10.1093\/eurheartj\/ehz754"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Skibitsky V.V., Opolskaya S.V., Fendrikova A.V. Antihypertensive efficacy of chronopharmacotherapeutical approach to arterial hypertension in post transient ischemic attack patients. Cardiovascular Therapy and Prevention. 2018;17(1):10\u20139. DOI: 10.15829\/1728-8800-2018-1-10-19","DOI":"10.15829\/1728-8800-2018-1-10-19"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021\u2013104. DOI: 10.1093\/eurheartj\/ehy339","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mancia G, Fagard R, Narkiewicz K, Red\u00f3n J, Zanchetti A, B\u00f6hm M et al. 2013 ESH\/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2013;31(7):1281\u2013357. DOI: 10.1097\/01.hjh.0000431740.32696.cc","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2016;29(4):277\u2013314. DOI: 10.1016\/j.echo.2016.01.011","DOI":"10.1016\/j.echo.2016.01.011"},{"key":"ref24","unstructured":"Naumov S.S. Chronobiology of stroke: the value of daily periodism. Medical Bulletin of the North Caucasus. 2009;4:76\u201380."},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ohashi N, Isobe S, Ishigaki S, Yasuda H. Circadian rhythm of blood pressure and the renin\u2013angiotensin system in the kidney. Hypertension Research. 2017;40(5):413\u201322. DOI: 10.1038\/hr.2016.166","DOI":"10.1038\/hr.2016.166"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Hermida RC, Smolensky MH, Balan H, Castriotta RJ, Crespo JJ, Dagan Y et al. Guidelines for the design and conduct of human clinical trials on ingestion-time differences \u2013 chronopharmacology and chronotherapy \u2013 of hypertension medications. Chronobiology International. 2021;38(1):1\u201326. DOI: 10.1080\/07420528.2020.1850468","DOI":"10.1080\/07420528.2020.1850468"},{"key":"ref27","unstructured":"Leonova M.V. Clinical pharmacology of angiotensin ii receptor blockers: valsartan. Medical Council. 2014;17:66\u201371."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Srinivasan V, Pandi-Perumal SR, Maestroni GJM, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotoxicity Research. 2005;7(4):293\u2013318. DOI: 10.1007\/BF03033887","DOI":"10.1007\/BF03033887"},{"key":"ref29","unstructured":"Grinenko T.N., Ballyuzek M.F., Kvetnaya T.V. Melatonin as a marker of intensity of structural and functional changes in the heart and vessels of the patients presenting with metabolic syndrome. Clinical Medicine. 2012;90(2):30\u20134."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zhang X, Li Z-L, Crane JA, Jordan KL, Pawar AS, Textor SC et al. Valsartan Regulates Myocardial Autophagy and Mitochondrial Turnover in Experimental Hypertension. Hypertension. 2014;64(1):87\u201393. DOI: 10.1161\/HYPERTENSIONAHA.113.02151","DOI":"10.1161\/HYPERTENSIONAHA.113.02151"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1854\/1098","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:18:00Z","timestamp":1793639880000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,30]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2021.11.n1854","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}